2633 — Jacobson Pharma Cashflow Statement
0.000.00%
Last trade - 00:00- HK$1.88bn
- HK$2.45bn
- HK$1.57bn
Annual cashflow statement for Jacobson Pharma, fiscal year end - March 31st, HKD millions except per share, conversion factor applied.
2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | 2026 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | 231 | 340 | 255 | 374 | 363 |
| Depreciation | |||||
| Non-Cash Items | 17.3 | 66.6 | 144 | 74.7 | 43.3 |
| Discontinued Operations | |||||
| Unusual Items | |||||
| Equity in Net Earnings/Losses | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -34.4 | 39.2 | -70.7 | -65.4 | -231 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Payable / Accrued Expenses | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | 407 | 630 | 484 | 527 | 328 |
| Capital Expenditures | -63.9 | -63 | -130 | -248 | -136 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 13.9 | -72 | 173 | -49.4 | -88.2 |
| Sale of Business | |||||
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Change in Net Investments | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -49.9 | -135 | 43.3 | -298 | -224 |
| Financing Cash Flow Items | -26.6 | -72.4 | -81.2 | -41.4 | -30.7 |
| Other Financing Cash Flow | |||||
| Total Cash Dividends Paid | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -358 | -36.6 | -1,053 | -131 | -242 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -1.7 | 458 | -524 | 97.1 | -139 |